FDA Has Lifted The Clinical Hold On GH Research's Investigational New Drug Application For GH001, Phase 3 Initiation Targeted For 2026
Benzinga Newsdesk 10 months ago
NewsHealth CareFDAGeneral
GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCompany to seek FDA alignment on global Phase 3 program replicating Phase 2b designPhase 3 initiation targeted for 2026
- GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment
- Company to seek FDA alignment on global Phase 3 program replicating Phase 2b design
- Phase 3 initiation targeted for 2026